JP2016535584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535584A5 JP2016535584A5 JP2016518089A JP2016518089A JP2016535584A5 JP 2016535584 A5 JP2016535584 A5 JP 2016535584A5 JP 2016518089 A JP2016518089 A JP 2016518089A JP 2016518089 A JP2016518089 A JP 2016518089A JP 2016535584 A5 JP2016535584 A5 JP 2016535584A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 101000658574 Homo sapiens Transmembrane 4 L6 family member 1 Proteins 0.000 claims description 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 14
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 claims description 12
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102000003964 Histone deacetylase Human genes 0.000 claims description 4
- 108090000353 Histone deacetylase Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 claims description 3
- -1 antibodies Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 claims description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 claims description 2
- 239000012626 DNA minor groove binder Substances 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 229940122429 Tubulin inhibitor Drugs 0.000 claims description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000013059 antihormonal agent Substances 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000007969 cellular immunity Effects 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000000941 radioactive substance Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 230000013595 glycosylation Effects 0.000 claims 4
- 238000006206 glycosylation reaction Methods 0.000 claims 4
- RRZVGDGTWNQAPW-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile Chemical compound C1=NN(C)C=C1CCN1C(C=2C=CC(=CC=2)C#N)=C(C2=CN(C)N=C2)N=C1 RRZVGDGTWNQAPW-UHFFFAOYSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 47
- 238000000034 method Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 102000055561 human TM4SF1 Human genes 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013068 control sample Substances 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019100296A JP6947777B2 (ja) | 2013-10-10 | 2019-05-29 | Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889340P | 2013-10-10 | 2013-10-10 | |
| US61/889,340 | 2013-10-10 | ||
| PCT/US2014/059761 WO2015054427A1 (en) | 2013-10-10 | 2014-10-08 | Tm4sf1 binding proteins and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019100296A Division JP6947777B2 (ja) | 2013-10-10 | 2019-05-29 | Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535584A JP2016535584A (ja) | 2016-11-17 |
| JP2016535584A5 true JP2016535584A5 (https=) | 2017-11-16 |
| JP6534654B2 JP6534654B2 (ja) | 2019-06-26 |
Family
ID=52813624
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518089A Active JP6534654B2 (ja) | 2013-10-10 | 2014-10-08 | Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法 |
| JP2019100296A Active JP6947777B2 (ja) | 2013-10-10 | 2019-05-29 | Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019100296A Active JP6947777B2 (ja) | 2013-10-10 | 2019-05-29 | Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10155812B2 (https=) |
| EP (1) | EP3054973B1 (https=) |
| JP (2) | JP6534654B2 (https=) |
| CN (1) | CN105934252B (https=) |
| AU (1) | AU2014331909B2 (https=) |
| CA (1) | CA2926087C (https=) |
| MX (1) | MX384984B (https=) |
| WO (1) | WO2015054427A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101781200B1 (ko) * | 2015-06-26 | 2017-09-22 | 차의과학대학교 산학협력단 | 비만 진단용 마커 tm4sf19 및 이를 이용한 방법 |
| US10265497B2 (en) | 2015-11-24 | 2019-04-23 | Massachusetts Institute Of Technology | Systems and methods for treating dementia |
| US10995126B2 (en) | 2016-05-04 | 2021-05-04 | National Health Research Institutes | Immunogenic peptide containing a b cell epitope of tumor associated antigen L6 |
| KR20250153860A (ko) | 2016-11-17 | 2025-10-27 | 코그니토 쎄라퓨틱스, 인코포레이티드 | 시각 자극을 통한 신경 자극 방법 및 시스템 |
| CN107216395B (zh) * | 2017-07-03 | 2018-07-20 | 上海科医联创生物科技有限公司 | 一种tm4sf1特异性嵌合抗原受体及其应用 |
| WO2019015696A2 (zh) * | 2017-07-17 | 2019-01-24 | 同济大学苏州研究院 | 用于治疗癌症的新靶标 |
| CN109265546B (zh) * | 2017-07-17 | 2022-05-24 | 同济大学苏州研究院 | 用于治疗癌症的新靶标 |
| EP3655961A4 (en) * | 2017-07-17 | 2021-09-01 | Massachusetts Institute of Technology | HEALTHY AND SICK BARRIER TISSUE CELL ATLAS |
| MX2020002241A (es) * | 2017-08-28 | 2020-09-03 | Angiex Inc | Anticuerpos anti-tm4sf y métodos de uso de los mismos. |
| US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
| KR102706443B1 (ko) | 2017-10-10 | 2024-09-11 | 메사추세츠 인스티튜트 오브 테크놀로지 | 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법 |
| JP7326764B2 (ja) * | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
| CA3103265A1 (en) | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
| US12428477B2 (en) * | 2019-02-27 | 2025-09-30 | Angiex, Inc. | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same |
| CN111426845B (zh) * | 2020-04-07 | 2021-06-15 | 中拓生物有限公司 | 一种血清载脂蛋白b测定试剂盒及其制备方法和应用 |
| WO2021222783A1 (en) * | 2020-05-01 | 2021-11-04 | Angiex, Inc. | Anti-tm4sf1 antibody drug conjugates and methods of using same |
| EP4204013A4 (en) * | 2020-08-26 | 2025-04-16 | Angiex, Inc. | ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USE THEREOF |
| AU2022245388A1 (en) * | 2021-03-26 | 2023-10-05 | Angiex, Inc. | Maytansine-antibody conjugates and methods of using same |
| EP4313144A4 (en) * | 2021-03-26 | 2025-08-20 | Angiex Inc | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPY AGENTS AND METHODS OF USE THEREOF |
| BR112023025305A2 (pt) * | 2021-06-03 | 2024-02-27 | Medpacto Inc | Composições farmacêuticas, proteína de fusão, e, uso do inibidor do membro 19 da família 4 l seis da transmembrana |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| JP2002539778A (ja) | 1999-03-19 | 2002-11-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４９個のヒト分泌タンパク質 |
| CA2391361A1 (en) * | 1999-06-11 | 2000-12-21 | Human Genome Sciences, Inc. | 47 human secreted proteins |
| BR0116024A (pt) | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
| WO2002060317A2 (en) * | 2001-01-30 | 2002-08-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
| BRPI0516048A (pt) | 2004-10-13 | 2008-08-19 | Crucell Holland B V E Beth Isr | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
| PE20061324A1 (es) * | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| EP2177630A1 (en) * | 2008-10-02 | 2010-04-21 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
| JPWO2010110346A1 (ja) * | 2009-03-24 | 2012-10-04 | 独立行政法人理化学研究所 | 白血病幹細胞マーカー |
| CN102459335B (zh) * | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| CA2809369A1 (en) | 2010-08-27 | 2012-03-01 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
-
2014
- 2014-10-08 WO PCT/US2014/059761 patent/WO2015054427A1/en not_active Ceased
- 2014-10-08 MX MX2016004579A patent/MX384984B/es unknown
- 2014-10-08 EP EP14851712.1A patent/EP3054973B1/en active Active
- 2014-10-08 CN CN201480060319.1A patent/CN105934252B/zh active Active
- 2014-10-08 AU AU2014331909A patent/AU2014331909B2/en active Active
- 2014-10-08 JP JP2016518089A patent/JP6534654B2/ja active Active
- 2014-10-08 CA CA2926087A patent/CA2926087C/en active Active
-
2016
- 2016-04-06 US US15/092,486 patent/US10155812B2/en active Active
-
2018
- 2018-11-06 US US16/181,674 patent/US10745479B2/en active Active
-
2019
- 2019-05-29 JP JP2019100296A patent/JP6947777B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535584A5 (https=) | ||
| US11760795B2 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer | |
| CN110177806B (zh) | 与met结合的抗met抗体、双特异性抗原结合分子及其使用方法 | |
| JP2026053616A (ja) | 癌の治療のためのクローディン１８．２に対する抗体を含む治療法 | |
| US20200399364A1 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2020531045A (ja) | 抗ｃｄ１６６抗体およびその使用 | |
| JP5324593B2 (ja) | マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法 | |
| CN103068851B (zh) | 内质蛋白的抗体及其用途 | |
| JP2021535142A (ja) | Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 | |
| CN102827287B (zh) | 用于诊断和治疗癌症的组合物和方法 | |
| KR100909290B1 (ko) | 항암 항체 | |
| CN105452292A (zh) | 使用结合细胞表面grp78的抗体进行癌症治疗 | |
| US12220604B2 (en) | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate | |
| CN102387815A (zh) | 用于治疗癌症的具鹅膏蕈毒素的靶结合部分 | |
| WO2021197359A1 (zh) | 一种构建多特异性抗体的平台 | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| WO2017139975A1 (en) | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine | |
| CN110382532A (zh) | 抗g-csf抗体及其用途 | |
| WO2023066389A1 (zh) | 靶向pd-1的双特异性抗体、及其制备和应用 | |
| EP2620449A1 (en) | Anti-ephrin-b2 antibody and use thereof | |
| CN116829184A (zh) | Mdna55和血管内皮生长因子a(vegf-a)的组合疗法 | |
| US20220195037A1 (en) | Compositions and methods for inhibiting cancer stem cells | |
| TWI793451B (zh) | 個人化癌症免疫治療 | |
| ES2348161T3 (es) | Métodos para dañar células usando funciones efectoras de anticuerpos anti-gfra1. | |
| TWI853396B (zh) | 跨膜和盤繞結構域家族3的特異性抗體及其用途 |